Molecular modelling of novel ADCY3 variant predicts a molecular target for tackling obesity

Int J Mol Med. 2022 Jan;49(1):10. doi: 10.3892/ijmm.2021.5065. Epub 2021 Nov 25.

Abstract

Severe early‑onset obesity is mainly attributed to single gene variations of the hypothalamic leptin‑melanocortin system, which is critical for controlling the balance between appetite and energy expenditure. Adenylate cyclase 3 (ADCY3), a transmembrane enzyme localized in primary neuronal cilia, is a key genetic candidate, which appears to have an essential role in regulating body weight. The present study aimed to identify ADCY3 genetic variants in severely obese young patients of Greek‑Cypriot origin by genomic sequencing. Apart from previously reported variants, the novel and probably pathogenic variant c.349T>A, causing a p.Leu117Met substitution within one of the two pseudo‑symmetric halves of the transmembrane part of the protein, was reported. Molecular modelling analysis used to delineate bonding interactions within the mutated protein structure strongly suggested a change in interactive forces and energy levels affecting the pseudo‑twofold symmetry of the transmembrane domain of the protein and probably its catalytic function. These results support the involvement of ADCY3 in the pathology of the disease and point towards the requirement of defining protein function and evaluating the clinical significance of the detected variants.

Keywords: ADCY3; body mass index; molecular modelling; obesity; variants.

MeSH terms

  • Adenylyl Cyclases / chemistry*
  • Adenylyl Cyclases / genetics*
  • Adolescent
  • Amino Acid Substitution
  • Cyprus
  • Female
  • Genetic Variation*
  • Humans
  • Male
  • Models, Molecular
  • Obesity / genetics*
  • Young Adult

Substances

  • Adenylyl Cyclases
  • adenylate cyclase 3

Grants and funding

This research received funding from the AG Leventis Foundation (grant no. 3317312) and the RCB Bank Ltd. (grant no. 33173151).